Developing dual-therapy applying IGF-1 & EPA for hepatic damage and intestinal adaptation in intestinal failure

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18032
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Kagoshima University
• Principal Investigator: MUTO Mitsuru 鹿児島大学, 医歯学域鹿児島大学病院, 講師 (70404522)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 腸管不全 / 短腸症候群 / ヒルシュスプルング病類縁疾患 / 炎症性腸疾患 / 静脈栄養関連肝障害 / 腸管不全関連肝障害 / 腸管順応 / 腸管リハビリテーション

Outline of Final Research Achievements

In this study, we focused on growth factor and ω3 fatty acids. Basic research was conducted to find a solution on the clinical problem in the liver and intestine in patients with intestinal failure. The growth factor we initially conceived of applying was insulin-like growth factor-1 (IGF-1), however, since it was difficult to obtain, then we started our experiments using hepatic growth factor as a substitute. In a rat model, growth factor was found to reduce parenteral nutrition-associated liver damage. And it was found that ω3 fatty acids, which are rich in eicosapenta hydrochloric acid (EPA), have the potency to induce intestinal mucosal growth.

Free Research Field

小児外科

Academic Significance and Societal Importance of the Research Achievements

新生児・乳児期に発生する腸管不全患児では、長期静脈栄養管理期間に惹起される難治性進行性の胆汁うっ滞性肝障害、静脈栄養関連肝障害(Parenteral nutrition-associated liver disease: PNALD)/腸管不全関連肝障害(Intestinal failure-associated liver disease: IFALD)を制御することが求められている。自己腸管における栄養吸収の促進をはかる諸治療を重ねるとともに、肝の庇護を担保する必要がある。今回の研究は、実臨床において両者を同時にすすめるための一助となるのではないか考えられる。